CONCERTA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CONCERTA (CONCERTA).
Methylphenidate is a central nervous system (CNS) stimulant. It blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their levels in the synaptic cleft. It also acts as a dopamine agonist by stimulating the release of dopamine from storage sites.
| Metabolism | Primarily hepatic via deesterification to ritalinic acid (inactive). Minor pathways include hydroxylation and oxidation. Not extensively metabolized by CYP450 enzymes. |
| Excretion | Primarily renal (77%-87% as unchanged drug and metabolites); metabolic elimination accounts for 13%-23%, with minor biliary excretion (<2%). |
| Half-life | Terminal elimination half-life of methylphenidate from CONCERTA is approximately 3.5 hours (range 2.5-5.5 hours) in adults; in children, mean half-life is 3-4 hours. The extended-release formulation provides a prolonged clinical effect due to the OROS delivery system, not prolonged half-life. |
| Protein binding | 10%-33% (mostly bound to albumin, less to alpha-1-acid glycoprotein). |
| Volume of Distribution | Vd approximately 2.65 L/kg (range 1.3-4.6 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Oral: 22% (low due to first-pass metabolism; relative bioavailability compared to immediate-release methylphenidate is 100% for total exposure, but with less peak-to-trough fluctuation). |
| Onset of Action | Oral: 1-2 hours (therapeutic effect begins at 1 hour, peak effect at 2-3 hours). |
| Duration of Action | Oral: 12 hours (due to OROS technology providing ascending release profile; clinical effect maintained for 12 hours after single dose). |
| Action Class | Sympthatomimmetics-ADHD |
| Brand Substitutes | Addwize OD 18mg Tablet |
18-72 mg orally once daily in the morning, starting at 18-36 mg/day and titrating in 18 mg increments weekly; maximum 72 mg/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | For GFR <30 mL/min/1.73 m² or ESRD, avoid use due to accumulation of methylphenidate metabolites. |
| Liver impairment | Child-Pugh Class C (severe impairment): reduce dose by 50%; no adjustment for Child-Pugh A or B, but monitor closely. |
| Pediatric use | Age ≥6 years: initial 18 mg once daily; titrate by 18 mg weekly to max 54 mg/day (6-12 years) or 72 mg/day (13-17 years); weight-based not required, but lower weight may benefit from lower starting doses. |
| Geriatric use | Start at lowest dose (18 mg daily); titrate cautiously due to increased sensitivity and higher risk of cardiovascular and psychiatric effects; monitor blood pressure and heart rate. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CONCERTA (CONCERTA).
| Breastfeeding | Excreted into breast milk; M/P ratio not established; limited data suggest low concentrations with typical maternal doses; monitor infant for agitation, insomnia, and poor weight gain; consider risk of long-term neurodevelopmental effects; breastfeeding not recommended unless essential. |
| Teratogenic Risk | First trimester: FDA Pregnancy Category C; animal studies showed increased risk of fetal malformations (e.g., cardiovascular, skeletal) at high doses; human data insufficient to define risk. Second trimester: No specific patterns of major malformations reported in limited human studies; may be associated with fetal growth restriction. Third trimester: Increased risk of neonatal adverse effects including withdrawal (e.g., irritability, hypertonia, poor feeding) and pulmonary hypertension; use only if benefit outweighs risk. |
■ FDA Black Box Warning
CONCERTA has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
| Serious Effects |
["Known hypersensitivity to methylphenidate or product components","Concurrent treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI","Glaucoma","Severe anxiety, tension, or agitation","Tics or family history of Tourette's syndrome","Severe hypertension, heart failure, arrhythmias, or recent myocardial infarction","Hyperthyroidism"]
| Precautions | ["Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities","Increased blood pressure and heart rate","Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior","Long-term suppression of growth in children","Potential for peripheral vasculopathy including Raynaud's phenomenon","Serotonin syndrome if co-administered with serotonergic drugs"] |
Loading safety data…
| Fetal Monitoring | Maternal: Blood pressure, heart rate, weight gain, psychiatric symptoms (e.g., anxiety, mania), and signs of abuse/dependence. Fetal: Serial ultrasound for growth restriction and oligohydramnios; consider fetal echocardiography if hypertension develops; assess for signs of prematurity and pulmonary hypertension at delivery. |
| Fertility Effects | Animal studies: No direct effect on fertility at therapeutic doses; human data insufficient. In females, possible disruption of menstrual cycle and reduced fertility secondary to appetite suppression and weight loss. In males, rare reports of erectile dysfunction and libido changes; reversibility typically occurs upon discontinuation. |